Metamark Genetics, Inc is determined to transform outcomes and improve survival for cancer patients by empowering personalized treatment decisions. Metamark is developing prognostic diagnostic tests, using its proprietary Prognosis Determinants™. These tests will contribute to optimized treatment of early stage cancer through knowledge of the tumor’s molecular characteristics and risk profile.

Our goal is to fundamentally change the way in which cancer is diagnosed and treated with the prospect of better survival and reduced morbidity for patients and significant cost savings for health care systems.

Quantitative multi-parameter assays that define risk of metastasis and recurrence by measuring the functional genetic elements that drive tumor aggressiveness. click here >

Metamark is building a world-class scientific team with the passion and determination to transform cancer care. To view our list of openings on our Careers page, click here >